Allogene Therapeutics Announces Participation in Investor Conferences
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a leading clinical-stage biotechnology company, is gearing up to participate in two prominent investor conferences in the near future. Known for its pioneering work in allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, Allogene is set to make a significant impact at these events.
Upcoming Investor Conferences
Mark your calendars for the following conferences where Allogene Therapeutics will be presenting:
Stifel 2024 Healthcare Conference
This conference is scheduled for a Monday morning engagement. Allogene will present on November 18, 2024, starting at 5:35 AM PT or 8:35 AM ET, showcasing its latest developments in cell therapy.
Jefferies London Healthcare Conference
Just days later, Allogene will also be featured at the Jefferies London Healthcare Conference on November 20, 2024, at 10:00 AM GMT or 5:00 AM ET. Attending this conference allows for direct insights into their innovative approach to healthcare.
Webcast Availability
For those interested in accessing these presentations, Allogene will provide any available webcasts on their official website. Visit www.allogene.com under the Investors tab in the News and Events section. After the live events, recordings will be made available for approximately 30 days, ensuring that investors have the opportunity to stay updated.
About Allogene Therapeutics
Headquartered in South San Francisco, Allogene Therapeutics is at the forefront of cell therapy innovations. The company focuses on developing allogeneic chimeric antigen receptor T cell products designed for broader accessibility and efficiency. Their team, boasting extensive experience in cell therapy, is dedicated to delivering these therapies to patients on-demand and at a scale that meets growing needs.
Company Mission and Goals
Allogene's mission revolves around effectively providing readily available treatments through enhanced cell therapy solutions. Their pipeline of 'off-the-shelf' CAR T candidates aims to revolutionize how cancer and autoimmune conditions are managed. This commitment to innovation is what sets Allogene apart as they prepare for future challenges in the biotechnology field.
Contacting Allogene Therapeutics
Interested parties can connect with Allogene for further inquiries. The Media/Investor Contact is Christine Cassiano, the Executive Vice President, and Chief Corporate Affairs & Brand Strategy Officer. Christine can be reached via email at Christine.Cassiano@allogene.com.
Frequently Asked Questions
What is Allogene Therapeutics known for?
Allogene Therapeutics specializes in developing allogeneic CAR T products for treating cancer and autoimmune diseases.
When will Allogene present at the investor conferences?
Allogene will present at the Stifel Healthcare Conference on November 18, 2024, and at the Jefferies London Healthcare Conference on November 20, 2024.
How can I watch the presentations from the conferences?
Webcasts of the presentations will be available on Allogene's website under the Investors tab, and replays will be accessible for about 30 days after the events.
What is the goal of Allogene Therapeutics?
The goal of Allogene is to make cell therapies accessible and efficient, providing patients with effective treatment options on-demand.
Who can I contact for more information about Allogene?
For information, you can contact Christine Cassiano at Allogene via the email address provided.